Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts?
Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 6,089,347 | $506,085,629 | -3% | 0.67% |
| 2. | AQR Capital Management Cliff Asness | 1,507,209 | $125,264,121 | +547% | 0.08% |
| 3. | D E Shaw D. E. Shaw | 584,098 | $48,544,385 | -14% | 0.03% |
| 4. | Driehaus Capital Richard Driehaus | 526,602 | $43,765,892 | +10% | 0.31% |
| 5. | Checkpoint Capital Sam Huang | 392,331 | $32,606,629 | +15% | 10.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing | |
| $22.80 | 1,109 | $25,285.20 | 3,208,235 | 2020-11-30 | Filing | |
| $22.81 | 361 | $8,232.79 | 3,207,126 | 2020-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.18 | 20,000 | $703,656.00 | 1,235 | 2026-01-06 | Filing | |
| $80.88 | 640 | $51,760.00 | 1,235 | 2025-12-02 | Filing | |
| $80.05 | 19,360 | $1,549,766.06 | 1,875 | 2025-12-02 | Filing | |
| $79.52 | 20,000 | $1,590,490.00 | 7,904 | 2025-12-01 | Filing | |
| $79.53 | 5,000 | $397,631.50 | 10,277 | 2025-12-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 507,967 | $19,404,339 | 0.03% | |
| 2. | 264,297 | $9,197,536 | 0.3% | |
| 3. | 245,093 | $8,529,236 | 0.01% | |
| 4. | 63,210 | $2,199,708 | 0.22% | |
| 5. | 56,946 | $1,981,721 | 0.07% |
News See All
13 Most Promising Growth Stocks According to Analysts
In today's market, shaped by continuous innovation and evolving macro backdrops, investors are wondering: which stocks to invest in? While many believe in investing in low-risk stocks, a large proportion...
12 Stocks that Will Bounce Back According to Wall Street Analysts
On January 5, Reuters reported that many analysts believe global investors will actively look for opportunities in undervalued areas of the financial markets in 2026.
Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch
On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target.
15 Stocks That Could Mint Millionaires in 2026
For more than a century, investing in the stock market in the United States has represented one of the most accessible paths to generating substantial wealth for the amateur investor, with a long and ...
Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts. On November 25, H.C.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock
As of the close of December 2, the consensus shows that analyst opinions are highly favourable towards Corcept Therapeutics Incorporated (NASDAQ:CORT), with 80% of analysts covering it assigning a Buy...
11 Best Stocks You'll Wish You Bought Sooner
Markets often reward those investors who spot inflection points before they become widely known.
Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a must-buy non-tech stock to invest in.
Hedge Fund Resource Center Billionaire Hedge Funds
